Table 3.
Annual evolution of BP (mm Hg/year) during the follow-up.
| NT (n = 434) | WCHT untreated (n = 399) | WCHT treated (n = 156) | ANOVA p < | |
|---|---|---|---|---|
| SBPc (mm Hg) | 1.2 ± 0.95 | −1.36 ± 1.35∗# | −2.03 ± 1.56∗ | 0.01 |
| DBPc (mm Hg) | 1.01 ± 0.77 | −0.98 ± 0.97# | −1.13 ± 0.75 | 0.01 |
| SBP 24 h (mm Hg) | 0.53 ± 0.93 | 0.76 ± 1.06∗# | 0.35 ± 1.01 | 0.01 |
| DBP 24 h (mm Hg) | 0.22 ± 0.95 | 0.39 ± 1.11∗# | 0.12 ± 0.71 | 0.01 |
| SBP daytime (mm Hg) | 0.54 ± 1.00 | 0.58 ± 1.48# | 0.37 ± 1.34 | 0.01 |
| DBP daytime (mm Hg) | 0.28 ± 1.05 | 0.38 ± 1.94# | 0.11 ± 0.92 | 0.01 |
| SBP nighttime (mm Hg) | 0.54 ± 0.84 | 0.63 ± 1.03# | 0.33 ± 0.92 | 0.01 |
| DBP nighttime (mm Hg) | 0.21 ± 0.89 | 0.33 ± 1.00# | 0.11 ± 0.87 | 0.01 |
NT, normotensives; WCHT, white-coat hypertensives; SBPc, office systolic BP; DBPc, office diastolic BP; HRc, office heart rate; Delta, difference between baseline and the end of the follow-up (final). Post hoc analysis: ∗p < 0.01 vs. NT #p < 0.01 different from WCHT treated.